Inivata Highlights its InVisionTM ctDNA Assay for Broad Molecular Profiling and Presentation of NSCLC data at ASCO Annual Meeting 2016
RESEARCH TRIANGLE PARK, North Carolina and CAMBRIDGE, England, June 1, 2016 /PRNewswire/ --
Inivata, a global clinical cancer genomics company employing the precision of circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, will introduce its proprietary InVisionTM ctDNA assay for broad molecular profiling during the 2016 Annual Meeting of the American Society of Clinical Oncology ('ASCO') at McCormick Place in Chicago, Illinois, June 3-7, 2016.
The InVisionTM assay utilizes the innovative application of Inivata's proprietary enhanced tagged-amplicon sequencing (eTAm-SeqTM) platform for genomic analysis, which was developed by Inivata on the basis of the TAm-SeqTM technology from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. InVisionTM was developed to serve as a reliable, multi-gene, support tool for oncologists to accurately translate genomic alterations into actionable information to inform clinical decision making and improve cancer treatment planning for the patient. Commercial availability of the InVisionTM assay will be the subject of a future announcement.
At ASCO, clinical data from the InVisionTM assay in non-small cell lung cancer is being co-presented with Institut Gustave Roussy. The following abstract will be presented during the poster session:
Abstract Title: Evaluation of liquid biopsies for molecular profiling and monitoring in non-small cell lung cancer (NSCLC) patients. (Abstract #: 11533)
Location: Poster Session: Tumor Biology, Hall A, Board Number 230
Date/Time: June 6th, 1:00 - 4:30pm
Presenter: Jordi Remon, MD
Author affiliations: Institut Gustave Roussy and Inivata
Inivata's representatives will also be exhibiting and providing further details on the impending commercial launch of the InVisionTM assay at the ASCO annual meeting booth number 6161. To arrange an interview or meeting please contact us via [email protected]
About Inivata
Inivata, a clinical cancer genomics company, is employing the precision of ctDNA analysis to improve personalised healthcare in oncology. Using a simple blood test, circulating tumour DNA (ctDNA) analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. Inivata's proprietary technology is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. Inivata's InVision[TM] ctDNA assay provides a highly sensitive analysis of a strategically selected gene panel to identify actionable mutations for oncologists to treat their patients optimally. For more information and a full listing of investors, please go to http://www.inivata.com. Follow us on twitter @Inivata
About ASCO Annual Meeting 2016
The American Society of Clinical Oncology ('ASCO') Annual Meeting brings together 30,000 oncology professionals from around the world. Educational sessions feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Science sessions present the latest ground-breaking research in oral and poster format.
The theme for ASCO 2016 is Collective Wisdom: The Future of Patient-Centered Care and Research.
Company Contact:
Liz Macfadyen
Email: [email protected]
Phone: +44(0)7739462323
Media Contacts
Consilium Strategic Communications
Chris Gardner/Laura Thornton
Phone: +44(0)20-3709-5700
[email protected]
SOURCE Inivata
Share this article